Liang-Chuan Wang

1.1k total citations
14 papers, 867 citations indexed

About

Liang-Chuan Wang is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Liang-Chuan Wang has authored 14 papers receiving a total of 867 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in Liang-Chuan Wang's work include CAR-T cell therapy research (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Immune Cell Function and Interaction (4 papers). Liang-Chuan Wang is often cited by papers focused on CAR-T cell therapy research (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Immune Cell Function and Interaction (4 papers). Liang-Chuan Wang collaborates with scholars based in United States, Slovakia and South Korea. Liang-Chuan Wang's co-authors include Steven Μ. Albelda, Edmund K. Moon, Michael C. Milone, Veena Kapoor, Carl H. June, Jing Sun, Ellen Puré, James L. Riley, Raghuveer Ranganathan and John Scholler and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.

In The Last Decade

Liang-Chuan Wang

12 papers receiving 854 citations

Peers

Countries citing papers authored by Liang-Chuan Wang

Since Specialization

Citations

This map shows the geographic impact of Liang-Chuan Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liang-Chuan Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liang-Chuan Wang more than expected).

Fields of papers citing papers by Liang-Chuan Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liang-Chuan Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liang-Chuan Wang. The network helps show where Liang-Chuan Wang may publish in the future.

Co-authorship network of co-authors of Liang-Chuan Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Liang-Chuan Wang. A scholar is included among the top collaborators of Liang-Chuan Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liang-Chuan Wang. Liang-Chuan Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Abstract 4861: INCA33890 increases CD8+ T-cell effector function compared with pembrolizumab as assessed by single-cell RNA sequencing in human PD-1xTGFβR2 knock-in mouse model 2025 ·Cancer Research ·Michelle Kinder, Lu Jin, Justine Carl, Lifeng Zhang, Paul Collier, Paul Waeltz, (unknown), (unknown), (unknown), Liang-Chuan Wang, Cynthia Timmers	0
2	Abstract 6071: PD-1xTGFβR2 bispecific Biclonics® antibody INCA33890 augments human T-cell effector functions in vitro and ex vivo 2025 ·Cancer Research ·Jun Guan, Aidan G. Gilmartin, Kenji Kimura, Estela Noguera-Ortega, Ashwini Kulkarni, (unknown), Michelle Kinder, Cynthia Timmers, (unknown), Patrick A. Mayes, Steven Μ. Albelda, (unknown), Liang-Chuan Wang	0
3	Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo 2020 ·Molecular Therapy ·Sarah A. Richman, Liang-Chuan Wang, Edmund K. Moon, Uday R. Khire, Steven Μ. Albelda, Michael C. Milone	69
4	814 MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that that does not show signs of peripheral toxicity 2020 ·SHILAP Revista de lepidopterología ·Kees Bol, Wilfred E. Marissen, (unknown), Paul J. Tacken, Steef Engels, Liang-Chuan Wang, Arpita Mondal, Mark Throsby, (unknown), Patrick A. Mayes, Cecile Geuijen	2
5	Abstract 4904: The BET inhibitor INCB054329 enhances the activity of checkpoint modulation in syngeneic tumor models 2016 ·Cancer Research ·Holly K. Koblish, Michael Hansbury, Leslie Hall, Liang-Chuan Wang, Yue Zhang, Maryanne Covington, Timothy C. Burn, Mark Rupar, Christine Gardiner, Thomas Condamine, (unknown), Matthew C. Stubbs, Eddy W. Yue, Richard Sparks, Thomas Maduskuie, Andrew P. Combs, Gregory Hollis, Reid Huber, (unknown), Peggy Scherle	4
6	Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors 2015 ·Cancer Immunology Research ·Enxiu Wang, Liang-Chuan Wang, Ching‐Yi Tsai, Vijay Bhoj, (unknown), Edmund K. Moon, Kheng Newick, Jing Sun, Albert Lo, Timothy Baradet, Michael D. Feldman, David M. Barrett, Ellen Puré, Steven Albelda, Michael C. Milone	91
7	Abstract C103: The combination of PI3kδ-selective inhibition and immunomodulation shows efficacy in solid tumor models 2015 ·Molecular Cancer Therapeutics ·Holly K. Koblish, Liang-Chuan Wang, Michael Hansbury, Yue Zhang, Gengjie Yang, Timothy C. Burn, Paul Waeltz, Mark Rupar, Eddy W. Yue, Brent Douty, Thomas Maduskuie, Nikoo Falahatpisheh, Yunlong Li, Andrew P. Combs, Gregory Hollis, Reid Huber, Peggy Scherle	5
8	Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors 2014 ·Clinical Cancer Research ·Edmund K. Moon, Liang-Chuan Wang, Douglas V. Dolfi, Caleph B. Wilson, Raghuveer Ranganathan, Jing Sun, Veena Kapoor, John Scholler, Ellen Puré, Michael C. Milone, Carl H. June, James L. Riley, E. John Wherry, Steven Μ. Albelda	344
9	Overcoming intrinsic inhibitory pathways to augment the antineoplastic activity of adoptively transferred T cells: Re-tuning your CAR before hitting a rocky road 2013 ·OncoImmunology ·Liang-Chuan Wang, Matthew J. Riese, Edmund K. Moon, Steven Μ. Albelda	6
10	Abstract A3: Enhanced effector responses in CAR-redirected CD8+ T cells deficient in diacylglycerol kinases. 2013 ·Cancer Research ·Matthew J. Riese, Liang-Chuan Wang, Anjana Ranganathan, Gary A. Koretzky, Steven Μ. Albelda	1
11	Thrombospondin-1 mediates oncogenic Ras–induced senescence in premalignant lung tumors 2013 ·Journal of Clinical Investigation ·Kwan‐Hyuck Baek, Dong‐Ha Bhang, A. Zaslavsky, Liang-Chuan Wang, Anil Vachani, Carla F. Kim, Steven Μ. Albelda, Gérard I. Evan, Sandra Ryeom	49
12	Mesothelin, a novel immunotherapy target for triple negative breast cancer 2012 ·Breast Cancer Research and Treatment ·Julia Tchou, Liang-Chuan Wang, (unknown), Hongtao Zhang, José R. Conejo-García, Hossein Borghaei, Michael Kalos, (unknown), Steven Μ. Albelda, Carl H. June, Paul J. Zhang	131
13	The receptor for advanced glycation end products mediates lung endothelial activation by RBCs 2012 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Nilam S. Mangalmurti, (unknown), Liang-Chuan Wang, Donna B. Stolz, Geetha Muthukumaran, Don L. Siegel, Ann Marie Schmidt, Janet Lee, Steven Μ. Albelda	20
14	Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery 2012 ·Proceedings of the National Academy of Sciences ·Jarrod D. Predina, Evgeniy Eruslanov, Brendan F. Judy, Veena Kapoor, Guanjun Cheng, Liang-Chuan Wang, Jing Sun, Edmund K. Moon, Zvi G. Fridlender, Steven Μ. Albelda, Sunil Singhal	145

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact